Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sarah Markham has a total of 422 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Enhancing Inclusivity in Patient-Reported Outcome Measure Completion: A Qualitative Analysis of Patient-Reported Barriers and Solutions

    by Christel McMullan, Joseph W. Lanario, Ameeta Retzer, Samantha Cruz Rivera, Foram Khatsuria, Sarah E. Hughes, Felicity Gaete Carvajal, Philip Collis, Roger Wilson, Kamil Sterniczuk, et al.

    Background: Patient-reported outcome measures (PROMs) are widely used in clinical care and research, yet barriers related to language, literacy, culture, accessibility, and digital exclusion may limit participation among underserved populations. This study explored patient perspectives on PROM completion to identify barriers, facilitators, and potential solutions to support equitable engagement. Methods: Semi-structured interviews were conducted with adults recruited from outpatient clinics at two NHS trusts in England between June 2024 and March 2026. Participants discussed their experiences and views of PROM completion across research and clinical settings. Interviews were analysed using inductive thematic analysis. Findings: Twenty-three participants were interviewed. Participants were more willing to complete PROMs when they were relevant, meaningful, and clearly linked to improving healthcare. Facilitators included clear wording, reduced questionnaire burden, flexible completion options, and accessible design. Participants emphasised the importance of cultural and linguistic relevance and support for diverse literacy, sensory, and digital needs. While electronic and AI-enabled approaches were viewed as convenient and efficient, concerns about privacy, trust, and reduced personal interaction influenced acceptability. Across all themes, human presence and support was valued for providing clarification, reassurance, accessibility, and meaningful engagement. Interpretation: PROM inclusivity is shaped by questionnaire design, accessibility, mode of administration, technology, and human support. Participants viewed human interaction as a key enabler of trust, understanding, and participation, suggesting that digital technologies should complement rather than replace opportunities for personalised support.Inclusive PROM implementation requires flexible, person-centred approaches that combine accessible design, cultural sensitivity, technology, and human support to ensure diverse patient perspectives are represented.

  • pmsims: Simulation-Based Sample Size Tools for Prediction Models

    by Ewan Carr, Gordon Forbes, Ridwan Olaniran, Diana Shamsutdinova, Daniel Stahl, Sarah Markham, Felix Zimmer

    Provides a flexible, simulation-based toolkit for exploring how much data are needed to develop reliable prediction models. It works by repeatedly generating data, fitting models, and evaluating performance to show how sample size affects predictive accuracy, calibration, and overfitting. The package supports continuous, binary, and time-to-event outcomes and can be used with both regression-based modelling approaches and machine-learning methods. It is designed to help researchers plan studies, assess feasibility, and build more robust and generalisable models. The methods are described in Olaniran et al. (2026) and Shamsutdinova et al. (2026) .


  • Open Access

    Can discussions with patients and the public clarify missing data mechanisms for digital outcome measures?

    by Mia S. Tackney, Amber Steele, Marie-Louise Zeissler, Sofía S. Villar, Jeremy Dearling, Sarah Markham, Farheen Yameen, Melissa Cox, Curie Freeborn, Lorraine Hazlehurst, et al.

    Background: Analysis of clinical trials with missing data requires statistical assumptions. When novel digital outcome measures are used, it is particularly important to understand trial participants’ experiences with the device. This can illuminate the reasons for and specific patterns of missing data and help inform plausible missing data assumptions. Methods: A patient and public involvement and engagement (PPIE) activity bridged statistical concepts on missing data with lived experiences of individuals who had participated in studies with digital outcome measures. Ten PPIE contributors were involved in the activity, which was structured based on feedback from previous PPIE activities and comprised of three meetings, pre- and post-meeting surveys and shared resources (including an introductory video). The three meetings were aimed to (i) introduce key statistical concepts, discuss expectations and set the scene, (ii) discuss experiences of using digital devices in research studies, and (iii) consolidate learnings and implications. This serves as a structured approach to discussions on missing data which can be used in other settings with digital outcome measures. Results: Reasons for missing data were highly context dependent and varied according to the device, study population and environmental/cultural context. Reasons discussed included operational aspects of the device, unresolved technology issues, and practicalities in daily life such as weather or season affecting comfort and the need to remove devices for religious, exercise or hygiene activities. Previous experience of using digital devices and receiving feedback from devices influenced levels of engagement. Although contributors did not report disengaging with devices in ways directly related to the outcome being measured, informative missingness was considered as important. Conclusions: The PPIE activity was a feasible and valuable approach to exploring patient and public perspectives on the reasons for and patterns of missing data in digital outcome measures. Lived experience may shed light on reasons for missing data that may be overlooked by researchers. Incorporating PPIE discussions within ongoing trials may help inform the plausibility of assumptions, identify candidate auxiliary variables and improve trial conduct. For future PPIE activities, purposeful recruitment and providing different modes of engagement, such as anonymous surveys, are recommended.

  • Open Access

    What comes next for responsible AI in healthcare: An international multi-stakeholder perspective on building interconnected health-system infrastructure for implementation (Preprint)

    by Raquel Iniesta, Albert Royo, Manuel Armayones, Rupa Chilvers, Sara Cerdas, Susan Shelmerdine, Payam Barnaghi, Ellie Asgari, Beatrix Fletcher, Sara Roda, et al.

    UNSTRUCTURED The central challenge facing AI in healthcare is no longer the absence of ethical guidance. Rather, it is the need for sufficiently developed and integrated organisational, regulatory, technical, operational, and educational infrastructure to translate ethical principles into routine practice. Existing implementation frameworks have made important advances in translating ethical principles into guidance across the AI lifecycle. However, responsible AI implementation also requires broader health-system infrastructure and capabilities that extend beyond individual AI systems. Building on these efforts, this roadmap takes a broader health-system perspective, focusing on the interconnected infrastructure and capabilities needed to enable responsible AI implementation across healthcare. Through a multi-stakeholder deliberative process involving two international convenings, followed by iterative synthesis and refinement by contributors, we developed a roadmap comprising five interconnected implementation pillars. These are: (1) ethical governance across the AI lifecycle; (2) regulatory and implementation coherence and governance alignment; (3) fair, explainable, trustworthy, and empowering AI; (4) operational tools and governance mechanisms; and (5) AI literacy, capacity building, and inclusive participation. The roadmap translates these priorities into health-system infrastructure and capabilities, priority actions, and the stakeholders with key roles in their implementation. Together, the five pillars frame responsible AI as an interconnected health-system implementation challenge requiring coordinated action across the healthcare ecosystem.

  • Open Access

    Factors associated with infection-related hospitalisations in severe mental illness: a retrospective cohort study

    by Amy Ronaldson, Sarah Markham, Alex Dregan, Temi Lampejo, Jayati Das-Munshi, Matthew Broadbent, Claire Henderson, Robert Stewart, Ioannis Bakolis

    Background: People with severe mental illness (SMI) have a higher risk of infection-related hospitalisations than the general population, yet the reasons why remain poorly understood. Objective: We aimed to identify factors associated with infection-related hospitalisations and to explore how these factors cluster together within the patient population. Methods: We conducted a retrospective cohort study using linked electronic health records from a large secondary mental health service in South London. Individuals with an SMI diagnosis between 1 January 2007 and 31 December 2019 were included. Cox regression models examined associations between a wide range of sociodemographic, health-related, clinical and treatment and service-use factors and time to first infection-related hospitalisation. Significant factors were then used in a hierarchical cluster analysis to identify distinct patterns. Findings: In 19 995 individuals with SMI, several factors associated with infection-related hospitalisations emerged, with the strongest being number of general hospital admissions for ambulatory care sensitive conditions (HR=2.31, 95% CI 2.08 to 2.56), clozapine prescribing (HR=1.67, 95% CI 1.45 to 1.92) and severe problems with physical illness/disability (HR=1.36, 95% CI 1.31 to 1.42). Two distinct patterns emerged: one characterised by older age, dementia and poor physical health; the other by younger age with complex psychiatric needs and use of alcohol and other substances. Conclusions1: This study identified several factors associated with infection-related hospitalisations and highlighted how these factors tend to group together among people with SMI. Clinical implications: These findings indicate potential areas where tailored prevention and monitoring strategies may be warranted to help reduce the likelihood of infection-related hospitalisation in people with SMI alongside broader measures such as prioritisation for pneumococcal and influenza vaccination.

  • Open Access

    Small numbers of clusters in cluster randomised trials: a scoping review of problems and proposed solutions

    by Olivier Quintin, Jessica Kasza, Nathan Davies, Sarah Markham, Richard Hooper

  • Open Access

    How Lived Experience Advisory Groups Contribute to the Design and Conduct of Mental Health Research

    by Jo Evans, Samuel Keightley, Angela Sweeney, Rosie Hill, Ezekiel Khayri, Sarah Markham, Til Wykes

    Introduction: The positive impact of patient and public involvement (PPI) on the relevance, accessibility and acceptability of mental health research is well documented. Much of this reporting comes from researchers; less is known about the perspectives of PPI contributors. We are interested in exploring which issues people with lived experience (LE) prioritise when reviewing mental health research, with a view to identifying some of the underlying factors which facilitate or hinder those impacts. Methods: We conducted a reflexive thematic analysis of meeting minutes reviewing 233 studies from two PPI research advisory groups supported by the Maudsley Biomedical Research Centre over a period of 8 years. Results: Our results foreground participants' experiences and show that PPI contributors want a greater emphasis on relational ethics within mental health research practice. We have identified key issues that have the potential to have a positive effect on the whole research cycle. These include ensuring fully inclusive research designs and practices, having transparent processes and increasing researcher reflexivity regarding power dynamics, stigma and participants' experiences. Conclusion: This study demonstrates the potential that PPI has to supplement existing ethical processes and positively impact research processes. Patient or Public Contribution: People with lived experience of mental distress were involved throughout the study, including study design, data collection, synthesis and authorship.

  • Open Access

    Reporting of Cohort and Routinely Collected Data in Randomised Controlled Trial Protocols (SPIRIT-ROUTINE): extension checklist with explanation and elaboration

    by Patricia M Kearney, Megan McCarthy, Sandhya Rengarajan, Linda M O’KEeffe, Kerry Avery, An-Wen Chan, Declan Devane, Gwyneth Davies, Chris Gale, Lars G Hemkens, et al.

    Randomised controlled trials that use cohorts or health-and-care systems data, often known as routinely collected data—such as electronic health records, registries, or administrative claims—are becoming increasingly common. These trials have the potential to streamline recruitment, intervention delivery, follow-up (within trial and long term), and to lower costs. The lack of clear information governance pathways, heterogeneous data quality, delays in data recording and acquisition, and regulatory or ethical complexities undermine reproducibility and bias assessment when routinely collected data are used in trials. We introduce the SPIRIT-ROUTINE extension to the SPIRIT 2025 guideline: a checklist and explanation designed to improve the reporting of trial protocols that rely on cohorts or routinely collected data sources. Investigators, funders, ethics committees, journal editors, and peer reviewers can use the SPIRIT-ROUTINE extension to enhance completeness, transparency, and usability of such protocols to support better research, healthcare decisions, and patient outcomes.

  • Open Access

    Structural and Socioeconomic Global Variation in Major Depressive Disorder: A Systematic Review and Meta-Analysis

    by Nadia Ali, Giulio Emilio Brancati, Jennifer Dykxhoorn, Sarah Markham, Allan Young, Joseph Hayes, Sameer Jauhar

    Background: Major depressive disorder (MDD) represents a leading cause of global disability, yet prevalence estimates vary dramatically across countries. While individual-level risk factors are well-documented, the role of structural and socioeconomic determinants in explaining cross-national variation remains poorly understood. The present systematic review and meta-analysis aim to estimate pooled global prevalence of MDD, and evaluate the extent to which country-level structural and socioeconomic indicators explain cross-national variation.Methods: MEDLINE, PsycINFO, and EMBASE were searched for articles published in English from 2000 to July 2025. Studies were included if they reported lifetime prevalence and/or 12-month prevalence, defined as the proportion of participants meeting criteria for MDD or MDE at any point in the previous 12 months, according to ICD-10, DSM-IV, or DSM-5 criteria; (2) had at least 1,000 participants; and (3) were published in peer-reviewed journals. Study outcomes included lifetime and 12-month prevalence of MDD or MDE. Random-effects meta-analyses were performed to estimate pooled prevalence. Mixed-effects meta-regressions examined prevalence moderators.Outcomes: Forty-four population-based studies, including 60 independent samples from 44 countries across six continents and a total of 1,149,046 participants were included. Pooled lifetime prevalence was 10.2% (95% CI=8.5 to 11.9%) and 12-month prevalence was 4.9% (95% CI=4.2 to 5.6%). For lifetime prevalence, continent explained 47.8% of variance and income level contributed 10.4%, with upper-middle-income countries showing the lowest prevalence. For 12-month prevalence, employment rate was the only significant moderator (β=-0.07, p=0.04) in univariable analyses, with stronger protective effects in Asia (β=-0.29, p<0.01) and Africa (β=-0.23, p=0.04). Continent and income combined explained 60.7% of between-study lifetime variance, while continent and employment explained 30.7% of 12-month variance. Study-level moderators were mostly non-significant.Interpretation: Structural and socioeconomic determinants partially explain global MDD prevalence, with different factors driving lifetime versus 12-month prevalence, effects varying across continents. Region-specific mental-health strategies should address socioeconomic determinants alongside individual-level interventions.

  • Open Access

    The value of person-first language in forensic mental health services

    by Jack Tomlin, Asya Mitisheva, Sarah Kilbane, Sarah Markham, John Tully

    Summary: Labels in healthcare influence perceptions, treatment and stigma. Although they can aid diagnosis and guide care, pejorative labels can dehumanise and perpetuate prejudice. Person-first language, which foregrounds the individual rather than a condition or behaviour, has been linked to reduced blame, stigma and social distance across mental health and forensic populations. Evidence suggests it may foster empathy, recovery-oriented attitudes and rehabilitation, while challenging essentialist and pessimistic views of mental illness and offending. Limitations include minimising structural coercion and lived experience. This editorial explores the evidence, mechanisms and practical applications of person-first language in forensic mental health, advocating cautious implementation and further research.